Dazodalibep Meets Phase 3 Sjogren Disease Endpoint
Amgen reported that the approximately 621-participant OASIZ 301 trial met its Week 48 primary endpoint in adults with moderate-to-severe systemic Sjogren disease. Dazodalibep produced a statistically significant and company-characterized clinically meaningful improvement in ESSDAI,…
